论文部分内容阅读
应用北京Ⅰ型高剂量率后装机及施用器治疗宫颈癌248例,其中Ⅱ、Ⅲ期5年存活率分别为76.2％及46.8％。局部复发、未控两组A点剂量均比无癌存活组高,未控组剂量增高更明显(P<0.05)。本组Ⅱ、Ⅲ级直肠、膀胱放射反应率分别为4.0％及1.6％。有无放射性直肠炎两组的直肠吸收量无差别(P>0.05),无反应组A点剂量反而高于前者,这表明仅增加腔内放射剂量不是改善疗效的理想方法,以及用直肠的一个参考点或A点吸收量均不宜做为直肠吸收量的参考值。
248 cases of cervical cancer were treated with Beijing Type Ⅰ high dose rate post-installed and applicator. The 5-year survival rates of stage Ⅱ and stage Ⅲ were 76.2% and 46.8% respectively. Local recurrence and uncontrolled dose at point A in both groups were significantly higher than those in non-cancer survivors, and those in uncontrolled groups were more significant (P <0.05). The group Ⅱ, Ⅲ rectum, bladder radiation response rates were 4.0% and 1.6%. There was no difference in rectal uptake between the two groups (P> 0.05), but the dose at point A in the non-response group was higher than the former, indicating that only increasing intracavitary dose is not an ideal method to improve the curative effect, Reference point or A point absorption should not be used as a reference value for rectal absorption.